New monoamine oxidase inhibitor type B Azilect? in treatment of Parkinson's disease
According to modern concepts, the early use of symptomatic therapy in Parkinson's disease (PD) has a favorable effect on the motor function, as well as the quality of life of patients, decrease the risk of motor fluctuations and dyskinesias on the progression of the disease. Razagilin (Azilekt) is a high effective long-lasting irreversible inhibitor of type B monoamine oxidase. The drug has a good symptomatic effect as monotherapy in early stages PD and in combination with levodopa therapy for the full-scaled disease states, has a neuroprotective effect and modifies the course of the disease. Azilekt important features are: single daily intake without dose titration, no need for dose adjustment in elderly people. The use of the drug at different stages PD in various age patients is effective due to lack of effect on cognitive function, behavior and temper.

Keywords: inhibitors of type B monoamine oxidase, dopamine, antiparkinsonian drug, Parkinson's disease